CoChat
Cited by 218

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Open access
Strati, Paolo, Ahmed, Sairah, Furqan, Fateeha, Fayad, Luis E., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Horowitz, Sandra B., Feng, Lei, Sun, Ryan, Claussen, Catherine M., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh, Johncy, Swapna, Adkins, Sherry, Kebriaei, Partow, Shpall, Elizabeth J., Green, Michael R., Flowers, Christopher R., Westin, Jason, Neelapu, Sattva S. · 2021 · Blood

Abstract

Corticosteroids are commonly used for the management of severe toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their dose, duration, and timing may affect clinical efficacy. Here, we determined the impact of corticosteroids on clinical outcomes in patients with relapsed or refractory large B-cell lymphoma treated with standard of care anti-CD19 CAR T-cell therapy. Among 100 patients evaluated, 60 (60%) received corticosteroids for management of CAR T-cell therapy–associated toxicities. The median cumulative dexamethasone-equivalent dose was 186 mg (range, 8-1803) and the median duration of corticosteroid treatment was 9 days (range, 1-30). Corticosteroid treatment was started between days 0 and 7 in 45 (75%) patients and beyond day 7 in 15 (25%). After a median follow-up of 10 months (95% confidence interval, 8-12 months), use of higher cumulative dose of corticosteroids was associated with significantly shorter progression-free survival. More importantly, higher cumulative dose of corticosteroids, and prolonged and early use after CAR T-cell infusion were associated with significantly shorter overall survival. These results suggest that corticosteroids should be used at the lowest dose and for the shortest duration and their initiation should be delayed whenever clinically feasible while managing CAR T-cell therapy–associated toxicities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020008865

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 218

Metadata

Authors
Strati, P., Ahmed, S., Furqan, F., Fayad, L. E., Lee, H. J., Iyer, S. P., Nair, R., Nastoupil, L. J., Parmar, S., Rodriguez, M. A., Samaniego, F., Steiner, R. E., Wang, M., Pinnix, C. C., Horowitz, S. B., Feng, L., Sun, R., Claussen, C. M., Hawkins, M. C., Johnson, N. A., Singh, P., Mistry, H., Johncy, S., Adkins, S., Kebriaei, P., Shpall, E. J., Green, M. R., Flowers, C. R., Westin, J., & Neelapu, S. S.
Venue
Blood
Published
2021-02-03
Volume
137
Issue
23
Pages
3272-3276
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3128956257
Cited by
218
References
11
FWCI
11.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.